nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Simvastatin—atherosclerosis	0.064	0.106	CbGbCtD
Paroxetine—CYP2C8—Simvastatin—atherosclerosis	0.0484	0.0799	CbGbCtD
Paroxetine—CYP2C8—Pravastatin—atherosclerosis	0.0474	0.0782	CbGbCtD
Paroxetine—CYP2C8—Lovastatin—atherosclerosis	0.0474	0.0782	CbGbCtD
Paroxetine—CYP2D6—Niacin—atherosclerosis	0.0391	0.0645	CbGbCtD
Paroxetine—CYP2C9—Rosuvastatin—atherosclerosis	0.0363	0.06	CbGbCtD
Paroxetine—ABCB1—Ezetimibe—atherosclerosis	0.0353	0.0582	CbGbCtD
Paroxetine—CYP2C9—Simvastatin—atherosclerosis	0.0338	0.0557	CbGbCtD
Paroxetine—CYP2C9—Lovastatin—atherosclerosis	0.0331	0.0545	CbGbCtD
Paroxetine—CYP2C9—Pravastatin—atherosclerosis	0.0331	0.0545	CbGbCtD
Paroxetine—ABCB1—Simvastatin—atherosclerosis	0.0328	0.0541	CbGbCtD
Paroxetine—ABCB1—Pravastatin—atherosclerosis	0.0321	0.0529	CbGbCtD
Paroxetine—ABCB1—Lovastatin—atherosclerosis	0.0321	0.0529	CbGbCtD
Paroxetine—CYP2D6—Simvastatin—atherosclerosis	0.0309	0.051	CbGbCtD
Paroxetine—CYP2D6—Pravastatin—atherosclerosis	0.0302	0.0499	CbGbCtD
Paroxetine—CYP2D6—Lovastatin—atherosclerosis	0.0302	0.0499	CbGbCtD
Paroxetine—HTR2A—arteriole—atherosclerosis	0.00218	0.197	CbGeAlD
Paroxetine—HTR2A—vein—atherosclerosis	0.0013	0.117	CbGeAlD
Paroxetine—TACR1—connective tissue—atherosclerosis	0.000868	0.0783	CbGeAlD
Paroxetine—HTR2A—hindlimb—atherosclerosis	0.000865	0.078	CbGeAlD
Paroxetine—HTR2A—appendage—atherosclerosis	0.000742	0.0669	CbGeAlD
Paroxetine—TACR1—adipose tissue—atherosclerosis	0.000666	0.0601	CbGeAlD
Paroxetine—HTR2A—artery—atherosclerosis	0.00053	0.0478	CbGeAlD
Paroxetine—HTR2A—endothelium—atherosclerosis	0.000448	0.0404	CbGeAlD
Paroxetine—HTR2A—blood vessel—atherosclerosis	0.000413	0.0372	CbGeAlD
Paroxetine—CHRM2—cardiovascular system—atherosclerosis	0.000381	0.0344	CbGeAlD
Paroxetine—CHRM1—cardiovascular system—atherosclerosis	0.000347	0.0313	CbGeAlD
Paroxetine—Tinnitus—Pravastatin—atherosclerosis	0.00031	0.00124	CcSEcCtD
Paroxetine—Malaise—Lovastatin—atherosclerosis	0.000308	0.00123	CcSEcCtD
Paroxetine—Flushing—Pravastatin—atherosclerosis	0.000308	0.00123	CcSEcCtD
Paroxetine—Cardiac disorder—Pravastatin—atherosclerosis	0.000308	0.00123	CcSEcCtD
Paroxetine—Muscle spasms—Simvastatin—atherosclerosis	0.000307	0.00123	CcSEcCtD
Paroxetine—Vertigo—Lovastatin—atherosclerosis	0.000307	0.00123	CcSEcCtD
Paroxetine—Angioedema—Ezetimibe—atherosclerosis	0.000306	0.00122	CcSEcCtD
Paroxetine—Angiopathy—Niacin—atherosclerosis	0.000306	0.00122	CcSEcCtD
Paroxetine—Leukopenia—Lovastatin—atherosclerosis	0.000306	0.00122	CcSEcCtD
Paroxetine—Chills—Niacin—atherosclerosis	0.000303	0.00121	CcSEcCtD
Paroxetine—Malaise—Ezetimibe—atherosclerosis	0.000302	0.00121	CcSEcCtD
Paroxetine—Vision blurred—Simvastatin—atherosclerosis	0.000301	0.0012	CcSEcCtD
Paroxetine—Arrhythmia—Niacin—atherosclerosis	0.000301	0.0012	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.0003	0.0012	CcSEcCtD
Paroxetine—Tremor—Simvastatin—atherosclerosis	0.0003	0.0012	CcSEcCtD
Paroxetine—Alopecia—Niacin—atherosclerosis	0.000298	0.00119	CcSEcCtD
Paroxetine—Chills—Pravastatin—atherosclerosis	0.000298	0.00119	CcSEcCtD
Paroxetine—Insomnia—Rosuvastatin—atherosclerosis	0.000298	0.00119	CcSEcCtD
Paroxetine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000297	0.00119	CcSEcCtD
Paroxetine—Arrhythmia—Pravastatin—atherosclerosis	0.000297	0.00118	CcSEcCtD
Paroxetine—Palpitations—Ezetimibe—atherosclerosis	0.000296	0.00118	CcSEcCtD
Paroxetine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000296	0.00118	CcSEcCtD
Paroxetine—Anaemia—Simvastatin—atherosclerosis	0.000296	0.00118	CcSEcCtD
Paroxetine—Malnutrition—Niacin—atherosclerosis	0.000294	0.00117	CcSEcCtD
Paroxetine—Erythema—Niacin—atherosclerosis	0.000294	0.00117	CcSEcCtD
Paroxetine—Alopecia—Pravastatin—atherosclerosis	0.000293	0.00117	CcSEcCtD
Paroxetine—Cough—Ezetimibe—atherosclerosis	0.000293	0.00117	CcSEcCtD
Paroxetine—Angioedema—Simvastatin—atherosclerosis	0.000292	0.00117	CcSEcCtD
Paroxetine—Myalgia—Lovastatin—atherosclerosis	0.000291	0.00116	CcSEcCtD
Paroxetine—Arthralgia—Lovastatin—atherosclerosis	0.000291	0.00116	CcSEcCtD
Paroxetine—Chest pain—Lovastatin—atherosclerosis	0.000291	0.00116	CcSEcCtD
Paroxetine—Anxiety—Lovastatin—atherosclerosis	0.00029	0.00116	CcSEcCtD
Paroxetine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00029	0.00116	CcSEcCtD
Paroxetine—Hypertension—Ezetimibe—atherosclerosis	0.000289	0.00116	CcSEcCtD
Paroxetine—Flatulence—Niacin—atherosclerosis	0.000289	0.00116	CcSEcCtD
Paroxetine—Malaise—Simvastatin—atherosclerosis	0.000288	0.00115	CcSEcCtD
Paroxetine—Tension—Niacin—atherosclerosis	0.000288	0.00115	CcSEcCtD
Paroxetine—Discomfort—Lovastatin—atherosclerosis	0.000288	0.00115	CcSEcCtD
Paroxetine—Vertigo—Simvastatin—atherosclerosis	0.000287	0.00115	CcSEcCtD
Paroxetine—Leukopenia—Simvastatin—atherosclerosis	0.000286	0.00114	CcSEcCtD
Paroxetine—Chest pain—Ezetimibe—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Myalgia—Ezetimibe—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Arthralgia—Ezetimibe—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Nervousness—Niacin—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Flatulence—Pravastatin—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Dry mouth—Lovastatin—atherosclerosis	0.000285	0.00114	CcSEcCtD
Paroxetine—Tension—Pravastatin—atherosclerosis	0.000284	0.00113	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000283	0.00113	CcSEcCtD
Paroxetine—Dysgeusia—Pravastatin—atherosclerosis	0.000283	0.00113	CcSEcCtD
Paroxetine—Muscle spasms—Niacin—atherosclerosis	0.000282	0.00113	CcSEcCtD
Paroxetine—Discomfort—Ezetimibe—atherosclerosis	0.000282	0.00113	CcSEcCtD
Paroxetine—Pain—Rosuvastatin—atherosclerosis	0.000282	0.00112	CcSEcCtD
Paroxetine—Constipation—Rosuvastatin—atherosclerosis	0.000282	0.00112	CcSEcCtD
Paroxetine—Confusional state—Lovastatin—atherosclerosis	0.000281	0.00112	CcSEcCtD
Paroxetine—Nervousness—Pravastatin—atherosclerosis	0.000281	0.00112	CcSEcCtD
Paroxetine—Dry mouth—Ezetimibe—atherosclerosis	0.000279	0.00112	CcSEcCtD
Paroxetine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000279	0.00111	CcSEcCtD
Paroxetine—Muscle spasms—Pravastatin—atherosclerosis	0.000278	0.00111	CcSEcCtD
Paroxetine—Infection—Lovastatin—atherosclerosis	0.000277	0.00111	CcSEcCtD
Paroxetine—Vision blurred—Niacin—atherosclerosis	0.000277	0.00111	CcSEcCtD
Paroxetine—Confusional state—Ezetimibe—atherosclerosis	0.000276	0.0011	CcSEcCtD
Paroxetine—CHRM3—adipose tissue—atherosclerosis	0.000274	0.0247	CbGeAlD
Paroxetine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000274	0.00109	CcSEcCtD
Paroxetine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000273	0.00109	CcSEcCtD
Paroxetine—Vision blurred—Pravastatin—atherosclerosis	0.000272	0.00109	CcSEcCtD
Paroxetine—Chest pain—Simvastatin—atherosclerosis	0.000272	0.00109	CcSEcCtD
Paroxetine—Myalgia—Simvastatin—atherosclerosis	0.000272	0.00109	CcSEcCtD
Paroxetine—Arthralgia—Simvastatin—atherosclerosis	0.000272	0.00109	CcSEcCtD
Paroxetine—Infection—Ezetimibe—atherosclerosis	0.000272	0.00109	CcSEcCtD
Paroxetine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000271	0.00108	CcSEcCtD
Paroxetine—Anxiety—Simvastatin—atherosclerosis	0.000271	0.00108	CcSEcCtD
Paroxetine—Tremor—Pravastatin—atherosclerosis	0.000271	0.00108	CcSEcCtD
Paroxetine—ABCB1—blood vessel—atherosclerosis	0.000271	0.0244	CbGeAlD
Paroxetine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000269	0.00108	CcSEcCtD
Paroxetine—Discomfort—Simvastatin—atherosclerosis	0.000269	0.00107	CcSEcCtD
Paroxetine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000268	0.00107	CcSEcCtD
Paroxetine—Angioedema—Niacin—atherosclerosis	0.000268	0.00107	CcSEcCtD
Paroxetine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000268	0.00107	CcSEcCtD
Paroxetine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000268	0.00107	CcSEcCtD
Paroxetine—Anaemia—Pravastatin—atherosclerosis	0.000267	0.00107	CcSEcCtD
Paroxetine—Skin disorder—Ezetimibe—atherosclerosis	0.000266	0.00106	CcSEcCtD
Paroxetine—Angioedema—Pravastatin—atherosclerosis	0.000264	0.00106	CcSEcCtD
Paroxetine—Vertigo—Niacin—atherosclerosis	0.000264	0.00105	CcSEcCtD
Paroxetine—Syncope—Niacin—atherosclerosis	0.000263	0.00105	CcSEcCtD
Paroxetine—Confusional state—Simvastatin—atherosclerosis	0.000263	0.00105	CcSEcCtD
Paroxetine—Leukopenia—Niacin—atherosclerosis	0.000263	0.00105	CcSEcCtD
Paroxetine—Urticaria—Rosuvastatin—atherosclerosis	0.000262	0.00104	CcSEcCtD
Paroxetine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000261	0.00104	CcSEcCtD
Paroxetine—Oedema—Simvastatin—atherosclerosis	0.000261	0.00104	CcSEcCtD
Paroxetine—Malaise—Pravastatin—atherosclerosis	0.000261	0.00104	CcSEcCtD
Paroxetine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00026	0.00104	CcSEcCtD
Paroxetine—Vertigo—Pravastatin—atherosclerosis	0.00026	0.00104	CcSEcCtD
Paroxetine—Palpitations—Niacin—atherosclerosis	0.000259	0.00104	CcSEcCtD
Paroxetine—Infection—Simvastatin—atherosclerosis	0.000259	0.00104	CcSEcCtD
Paroxetine—Leukopenia—Pravastatin—atherosclerosis	0.000259	0.00103	CcSEcCtD
Paroxetine—Loss of consciousness—Niacin—atherosclerosis	0.000258	0.00103	CcSEcCtD
Paroxetine—Cough—Niacin—atherosclerosis	0.000256	0.00102	CcSEcCtD
Paroxetine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000256	0.00102	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000254	0.00102	CcSEcCtD
Paroxetine—Insomnia—Lovastatin—atherosclerosis	0.000252	0.00101	CcSEcCtD
Paroxetine—Cough—Pravastatin—atherosclerosis	0.000252	0.00101	CcSEcCtD
Paroxetine—Paraesthesia—Lovastatin—atherosclerosis	0.000251	0.001	CcSEcCtD
Paroxetine—Arthralgia—Niacin—atherosclerosis	0.00025	0.000998	CcSEcCtD
Paroxetine—Myalgia—Niacin—atherosclerosis	0.00025	0.000998	CcSEcCtD
Paroxetine—Hypertension—Pravastatin—atherosclerosis	0.00025	0.000997	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000249	0.000996	CcSEcCtD
Paroxetine—Dyspnoea—Lovastatin—atherosclerosis	0.000249	0.000994	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000248	0.000992	CcSEcCtD
Paroxetine—Insomnia—Ezetimibe—atherosclerosis	0.000248	0.000989	CcSEcCtD
Paroxetine—Arthralgia—Pravastatin—atherosclerosis	0.000246	0.000983	CcSEcCtD
Paroxetine—Myalgia—Pravastatin—atherosclerosis	0.000246	0.000983	CcSEcCtD
Paroxetine—Chest pain—Pravastatin—atherosclerosis	0.000246	0.000983	CcSEcCtD
Paroxetine—Paraesthesia—Ezetimibe—atherosclerosis	0.000246	0.000982	CcSEcCtD
Paroxetine—Dyspepsia—Lovastatin—atherosclerosis	0.000246	0.000981	CcSEcCtD
Paroxetine—Anxiety—Pravastatin—atherosclerosis	0.000245	0.00098	CcSEcCtD
Paroxetine—Dry mouth—Niacin—atherosclerosis	0.000244	0.000976	CcSEcCtD
Paroxetine—Dyspnoea—Ezetimibe—atherosclerosis	0.000244	0.000974	CcSEcCtD
Paroxetine—Discomfort—Pravastatin—atherosclerosis	0.000243	0.000971	CcSEcCtD
Paroxetine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000243	0.000969	CcSEcCtD
Paroxetine—Decreased appetite—Lovastatin—atherosclerosis	0.000243	0.000969	CcSEcCtD
Paroxetine—Dyspepsia—Ezetimibe—atherosclerosis	0.000241	0.000962	CcSEcCtD
Paroxetine—Fatigue—Lovastatin—atherosclerosis	0.000241	0.000961	CcSEcCtD
Paroxetine—Anaphylactic shock—Niacin—atherosclerosis	0.00024	0.000957	CcSEcCtD
Paroxetine—Oedema—Niacin—atherosclerosis	0.00024	0.000957	CcSEcCtD
Paroxetine—Pain—Lovastatin—atherosclerosis	0.000239	0.000953	CcSEcCtD
Paroxetine—Constipation—Lovastatin—atherosclerosis	0.000239	0.000953	CcSEcCtD
Paroxetine—Confusional state—Pravastatin—atherosclerosis	0.000238	0.00095	CcSEcCtD
Paroxetine—Decreased appetite—Ezetimibe—atherosclerosis	0.000238	0.00095	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000238	0.00095	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000236	0.000944	CcSEcCtD
Paroxetine—Asthenia—Rosuvastatin—atherosclerosis	0.000236	0.000943	CcSEcCtD
Paroxetine—Insomnia—Simvastatin—atherosclerosis	0.000236	0.000943	CcSEcCtD
Paroxetine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000236	0.000942	CcSEcCtD
Paroxetine—Oedema—Pravastatin—atherosclerosis	0.000236	0.000942	CcSEcCtD
Paroxetine—Fatigue—Ezetimibe—atherosclerosis	0.000236	0.000942	CcSEcCtD
Paroxetine—Shock—Niacin—atherosclerosis	0.000236	0.000942	CcSEcCtD
Paroxetine—Infection—Pravastatin—atherosclerosis	0.000234	0.000936	CcSEcCtD
Paroxetine—Paraesthesia—Simvastatin—atherosclerosis	0.000234	0.000936	CcSEcCtD
Paroxetine—Constipation—Ezetimibe—atherosclerosis	0.000234	0.000935	CcSEcCtD
Paroxetine—Pain—Ezetimibe—atherosclerosis	0.000234	0.000935	CcSEcCtD
Paroxetine—Tachycardia—Niacin—atherosclerosis	0.000234	0.000934	CcSEcCtD
Paroxetine—Pruritus—Rosuvastatin—atherosclerosis	0.000233	0.00093	CcSEcCtD
Paroxetine—Skin disorder—Niacin—atherosclerosis	0.000233	0.00093	CcSEcCtD
Paroxetine—Dyspnoea—Simvastatin—atherosclerosis	0.000233	0.000929	CcSEcCtD
Paroxetine—Hyperhidrosis—Niacin—atherosclerosis	0.000232	0.000925	CcSEcCtD
Paroxetine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000231	0.000923	CcSEcCtD
Paroxetine—Feeling abnormal—Lovastatin—atherosclerosis	0.00023	0.000918	CcSEcCtD
Paroxetine—Dyspepsia—Simvastatin—atherosclerosis	0.00023	0.000918	CcSEcCtD
Paroxetine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000228	0.000911	CcSEcCtD
Paroxetine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000228	0.000911	CcSEcCtD
Paroxetine—Decreased appetite—Simvastatin—atherosclerosis	0.000227	0.000906	CcSEcCtD
Paroxetine—CYP2B6—cardiovascular system—atherosclerosis	0.000226	0.0204	CbGeAlD
Paroxetine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000226	0.000901	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000225	0.0009	CcSEcCtD
Paroxetine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000225	0.0009	CcSEcCtD
Paroxetine—Fatigue—Simvastatin—atherosclerosis	0.000225	0.000899	CcSEcCtD
Paroxetine—Hypotension—Niacin—atherosclerosis	0.000224	0.000894	CcSEcCtD
Paroxetine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000224	0.000894	CcSEcCtD
Paroxetine—CYP2C9—cardiovascular system—atherosclerosis	0.000224	0.0202	CbGeAlD
Paroxetine—Constipation—Simvastatin—atherosclerosis	0.000223	0.000891	CcSEcCtD
Paroxetine—Pain—Simvastatin—atherosclerosis	0.000223	0.000891	CcSEcCtD
Paroxetine—Urticaria—Lovastatin—atherosclerosis	0.000222	0.000885	CcSEcCtD
Paroxetine—Body temperature increased—Lovastatin—atherosclerosis	0.000221	0.000881	CcSEcCtD
Paroxetine—Abdominal pain—Lovastatin—atherosclerosis	0.000221	0.000881	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000218	0.000872	CcSEcCtD
Paroxetine—Dizziness—Rosuvastatin—atherosclerosis	0.000218	0.00087	CcSEcCtD
Paroxetine—Urticaria—Ezetimibe—atherosclerosis	0.000217	0.000868	CcSEcCtD
Paroxetine—Insomnia—Niacin—atherosclerosis	0.000217	0.000866	CcSEcCtD
Paroxetine—Abdominal pain—Ezetimibe—atherosclerosis	0.000216	0.000864	CcSEcCtD
Paroxetine—Body temperature increased—Ezetimibe—atherosclerosis	0.000216	0.000864	CcSEcCtD
Paroxetine—Paraesthesia—Niacin—atherosclerosis	0.000215	0.000859	CcSEcCtD
Paroxetine—Feeling abnormal—Simvastatin—atherosclerosis	0.000215	0.000859	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000215	0.000859	CcSEcCtD
Paroxetine—Dyspnoea—Niacin—atherosclerosis	0.000214	0.000853	CcSEcCtD
Paroxetine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000213	0.000852	CcSEcCtD
Paroxetine—Insomnia—Pravastatin—atherosclerosis	0.000213	0.000852	CcSEcCtD
Paroxetine—Somnolence—Niacin—atherosclerosis	0.000213	0.000851	CcSEcCtD
Paroxetine—Paraesthesia—Pravastatin—atherosclerosis	0.000212	0.000846	CcSEcCtD
Paroxetine—HTR2A—connective tissue—atherosclerosis	0.000212	0.0191	CbGeAlD
Paroxetine—Dyspepsia—Niacin—atherosclerosis	0.000211	0.000843	CcSEcCtD
Paroxetine—Dyspnoea—Pravastatin—atherosclerosis	0.00021	0.00084	CcSEcCtD
Paroxetine—Decreased appetite—Niacin—atherosclerosis	0.000208	0.000832	CcSEcCtD
Paroxetine—Dyspepsia—Pravastatin—atherosclerosis	0.000208	0.00083	CcSEcCtD
Paroxetine—Rash—Rosuvastatin—atherosclerosis	0.000208	0.000829	CcSEcCtD
Paroxetine—Dermatitis—Rosuvastatin—atherosclerosis	0.000207	0.000828	CcSEcCtD
Paroxetine—Urticaria—Simvastatin—atherosclerosis	0.000207	0.000828	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000207	0.000826	CcSEcCtD
Paroxetine—Body temperature increased—Simvastatin—atherosclerosis	0.000206	0.000824	CcSEcCtD
Paroxetine—Abdominal pain—Simvastatin—atherosclerosis	0.000206	0.000824	CcSEcCtD
Paroxetine—Headache—Rosuvastatin—atherosclerosis	0.000206	0.000824	CcSEcCtD
Paroxetine—Hypersensitivity—Lovastatin—atherosclerosis	0.000206	0.000821	CcSEcCtD
Paroxetine—Decreased appetite—Pravastatin—atherosclerosis	0.000205	0.000819	CcSEcCtD
Paroxetine—Pain—Niacin—atherosclerosis	0.000205	0.000818	CcSEcCtD
Paroxetine—Fatigue—Pravastatin—atherosclerosis	0.000203	0.000812	CcSEcCtD
Paroxetine—Pain—Pravastatin—atherosclerosis	0.000202	0.000806	CcSEcCtD
Paroxetine—Constipation—Pravastatin—atherosclerosis	0.000202	0.000806	CcSEcCtD
Paroxetine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000202	0.000805	CcSEcCtD
Paroxetine—Asthenia—Lovastatin—atherosclerosis	0.0002	0.0008	CcSEcCtD
Paroxetine—Pruritus—Lovastatin—atherosclerosis	0.000197	0.000788	CcSEcCtD
Paroxetine—Asthenia—Ezetimibe—atherosclerosis	0.000196	0.000784	CcSEcCtD
Paroxetine—Gastrointestinal pain—Niacin—atherosclerosis	0.000196	0.000783	CcSEcCtD
Paroxetine—Nausea—Rosuvastatin—atherosclerosis	0.000196	0.000781	CcSEcCtD
Paroxetine—Feeling abnormal—Pravastatin—atherosclerosis	0.000194	0.000777	CcSEcCtD
Paroxetine—Pruritus—Ezetimibe—atherosclerosis	0.000194	0.000773	CcSEcCtD
Paroxetine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000193	0.000771	CcSEcCtD
Paroxetine—Hypersensitivity—Simvastatin—atherosclerosis	0.000192	0.000768	CcSEcCtD
Paroxetine—Diarrhoea—Lovastatin—atherosclerosis	0.000191	0.000762	CcSEcCtD
Paroxetine—Urticaria—Niacin—atherosclerosis	0.00019	0.00076	CcSEcCtD
Paroxetine—Body temperature increased—Niacin—atherosclerosis	0.000189	0.000757	CcSEcCtD
Paroxetine—Abdominal pain—Niacin—atherosclerosis	0.000189	0.000757	CcSEcCtD
Paroxetine—Urticaria—Pravastatin—atherosclerosis	0.000187	0.000749	CcSEcCtD
Paroxetine—Asthenia—Simvastatin—atherosclerosis	0.000187	0.000748	CcSEcCtD
Paroxetine—Diarrhoea—Ezetimibe—atherosclerosis	0.000187	0.000748	CcSEcCtD
Paroxetine—Body temperature increased—Pravastatin—atherosclerosis	0.000187	0.000745	CcSEcCtD
Paroxetine—Abdominal pain—Pravastatin—atherosclerosis	0.000187	0.000745	CcSEcCtD
Paroxetine—Pruritus—Simvastatin—atherosclerosis	0.000185	0.000737	CcSEcCtD
Paroxetine—Dizziness—Lovastatin—atherosclerosis	0.000184	0.000737	CcSEcCtD
Paroxetine—HTR2A—cardiovascular system—atherosclerosis	0.000184	0.0166	CbGeAlD
Paroxetine—Dizziness—Ezetimibe—atherosclerosis	0.000181	0.000723	CcSEcCtD
Paroxetine—Diarrhoea—Simvastatin—atherosclerosis	0.000179	0.000713	CcSEcCtD
Paroxetine—Vomiting—Lovastatin—atherosclerosis	0.000177	0.000709	CcSEcCtD
Paroxetine—Hypersensitivity—Niacin—atherosclerosis	0.000177	0.000705	CcSEcCtD
Paroxetine—Rash—Lovastatin—atherosclerosis	0.000176	0.000703	CcSEcCtD
Paroxetine—Dermatitis—Lovastatin—atherosclerosis	0.000176	0.000702	CcSEcCtD
Paroxetine—Headache—Lovastatin—atherosclerosis	0.000175	0.000698	CcSEcCtD
Paroxetine—Vomiting—Ezetimibe—atherosclerosis	0.000174	0.000695	CcSEcCtD
Paroxetine—Hypersensitivity—Pravastatin—atherosclerosis	0.000174	0.000694	CcSEcCtD
Paroxetine—Dizziness—Simvastatin—atherosclerosis	0.000173	0.000689	CcSEcCtD
Paroxetine—Rash—Ezetimibe—atherosclerosis	0.000173	0.000689	CcSEcCtD
Paroxetine—Dermatitis—Ezetimibe—atherosclerosis	0.000172	0.000689	CcSEcCtD
Paroxetine—Asthenia—Niacin—atherosclerosis	0.000172	0.000687	CcSEcCtD
Paroxetine—Headache—Ezetimibe—atherosclerosis	0.000171	0.000685	CcSEcCtD
Paroxetine—Pruritus—Niacin—atherosclerosis	0.00017	0.000677	CcSEcCtD
Paroxetine—Asthenia—Pravastatin—atherosclerosis	0.000169	0.000676	CcSEcCtD
Paroxetine—Pruritus—Pravastatin—atherosclerosis	0.000167	0.000667	CcSEcCtD
Paroxetine—Vomiting—Simvastatin—atherosclerosis	0.000166	0.000663	CcSEcCtD
Paroxetine—Nausea—Lovastatin—atherosclerosis	0.000166	0.000662	CcSEcCtD
Paroxetine—Rash—Simvastatin—atherosclerosis	0.000165	0.000657	CcSEcCtD
Paroxetine—Dermatitis—Simvastatin—atherosclerosis	0.000164	0.000657	CcSEcCtD
Paroxetine—Diarrhoea—Niacin—atherosclerosis	0.000164	0.000655	CcSEcCtD
Paroxetine—Headache—Simvastatin—atherosclerosis	0.000163	0.000653	CcSEcCtD
Paroxetine—Nausea—Ezetimibe—atherosclerosis	0.000163	0.000649	CcSEcCtD
Paroxetine—Diarrhoea—Pravastatin—atherosclerosis	0.000161	0.000645	CcSEcCtD
Paroxetine—Dizziness—Niacin—atherosclerosis	0.000158	0.000633	CcSEcCtD
Paroxetine—Dizziness—Pravastatin—atherosclerosis	0.000156	0.000623	CcSEcCtD
Paroxetine—CYP2C8—liver—atherosclerosis	0.000156	0.014	CbGeAlD
Paroxetine—Nausea—Simvastatin—atherosclerosis	0.000155	0.000619	CcSEcCtD
Paroxetine—Vomiting—Niacin—atherosclerosis	0.000152	0.000609	CcSEcCtD
Paroxetine—Rash—Niacin—atherosclerosis	0.000151	0.000603	CcSEcCtD
Paroxetine—Dermatitis—Niacin—atherosclerosis	0.000151	0.000603	CcSEcCtD
Paroxetine—Headache—Niacin—atherosclerosis	0.00015	0.0006	CcSEcCtD
Paroxetine—Vomiting—Pravastatin—atherosclerosis	0.00015	0.000599	CcSEcCtD
Paroxetine—Rash—Pravastatin—atherosclerosis	0.000149	0.000594	CcSEcCtD
Paroxetine—Dermatitis—Pravastatin—atherosclerosis	0.000149	0.000594	CcSEcCtD
Paroxetine—Headache—Pravastatin—atherosclerosis	0.000148	0.00059	CcSEcCtD
Paroxetine—Nausea—Niacin—atherosclerosis	0.000142	0.000569	CcSEcCtD
Paroxetine—Nausea—Pravastatin—atherosclerosis	0.00014	0.00056	CcSEcCtD
Paroxetine—CYP2B6—liver—atherosclerosis	0.00014	0.0126	CbGeAlD
Paroxetine—CYP2C9—liver—atherosclerosis	0.000138	0.0125	CbGeAlD
Paroxetine—ABCB1—cardiovascular system—atherosclerosis	0.000121	0.0109	CbGeAlD
Paroxetine—HTR2A—liver—atherosclerosis	0.000114	0.0103	CbGeAlD
Paroxetine—ABCB1—adipose tissue—atherosclerosis	0.000106	0.0096	CbGeAlD
Paroxetine—CYP2D6—liver—atherosclerosis	0.000104	0.00936	CbGeAlD
Paroxetine—ABCB1—liver—atherosclerosis	7.47e-05	0.00673	CbGeAlD
Paroxetine—CHRM2—Signaling Pathways—PRKCG—atherosclerosis	9.45e-06	7.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPP1—atherosclerosis	9.38e-06	7.08e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HMOX1—atherosclerosis	9.35e-06	7.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	9.34e-06	7.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPP1—atherosclerosis	9.33e-06	7.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPP1—atherosclerosis	9.3e-06	7.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	9.29e-06	7.01e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL8—atherosclerosis	9.26e-06	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPP1—atherosclerosis	9.21e-06	6.95e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SERPINE1—atherosclerosis	9.2e-06	6.95e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—atherosclerosis	9.18e-06	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NOS3—atherosclerosis	9.17e-06	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL8—atherosclerosis	9.17e-06	6.92e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—atherosclerosis	9.09e-06	6.87e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.98e-06	6.78e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOB—atherosclerosis	8.96e-06	6.76e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.95e-06	6.76e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARA—atherosclerosis	8.92e-06	6.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CG—atherosclerosis	8.88e-06	6.71e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCA1—atherosclerosis	8.87e-06	6.7e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NOS3—atherosclerosis	8.78e-06	6.63e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—atherosclerosis	8.71e-06	6.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	8.68e-06	6.55e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGT—atherosclerosis	8.64e-06	6.53e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	8.63e-06	6.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PDGFB—atherosclerosis	8.6e-06	6.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—atherosclerosis	8.57e-06	6.47e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—LPL—atherosclerosis	8.55e-06	6.46e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PDGFB—atherosclerosis	8.52e-06	6.43e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—atherosclerosis	8.47e-06	6.4e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—atherosclerosis	8.47e-06	6.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—atherosclerosis	8.43e-06	6.36e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—atherosclerosis	8.41e-06	6.35e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—atherosclerosis	8.4e-06	6.34e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CAV1—atherosclerosis	8.39e-06	6.33e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOA1—atherosclerosis	8.37e-06	6.32e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—atherosclerosis	8.34e-06	6.3e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—atherosclerosis	8.32e-06	6.28e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—atherosclerosis	8.3e-06	6.27e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—atherosclerosis	8.3e-06	6.27e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—atherosclerosis	8.26e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—atherosclerosis	8.26e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—atherosclerosis	8.23e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—atherosclerosis	8.23e-06	6.21e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	8.22e-06	6.21e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	8.2e-06	6.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CAV1—atherosclerosis	8.18e-06	6.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOA1—atherosclerosis	8.16e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CAV1—atherosclerosis	8.15e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—atherosclerosis	8.15e-06	6.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—atherosclerosis	8.15e-06	6.15e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—atherosclerosis	8.15e-06	6.15e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	8.14e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOA1—atherosclerosis	8.13e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CD36—atherosclerosis	8.12e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CAV1—atherosclerosis	8.07e-06	6.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOA1—atherosclerosis	8.06e-06	6.08e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	7.92e-06	5.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—atherosclerosis	7.88e-06	5.95e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	7.86e-06	5.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—atherosclerosis	7.86e-06	5.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—F2—atherosclerosis	7.83e-06	5.91e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOB—atherosclerosis	7.8e-06	5.89e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	7.79e-06	5.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—F2—atherosclerosis	7.79e-06	5.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—atherosclerosis	7.78e-06	5.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—F2—atherosclerosis	7.76e-06	5.86e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—atherosclerosis	7.74e-06	5.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—atherosclerosis	7.71e-06	5.82e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—atherosclerosis	7.7e-06	5.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—F2—atherosclerosis	7.69e-06	5.8e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.68e-06	5.8e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CG—atherosclerosis	7.64e-06	5.77e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—atherosclerosis	7.61e-06	5.75e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—atherosclerosis	7.59e-06	5.73e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARA—atherosclerosis	7.55e-06	5.7e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	7.53e-06	5.68e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	7.49e-06	5.66e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	7.45e-06	5.63e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LPL—atherosclerosis	7.45e-06	5.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	7.43e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—atherosclerosis	7.41e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—atherosclerosis	7.37e-06	5.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NOS3—atherosclerosis	7.37e-06	5.57e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—atherosclerosis	7.36e-06	5.56e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	7.35e-06	5.55e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOB—atherosclerosis	7.35e-06	5.55e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—atherosclerosis	7.32e-06	5.52e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOB—atherosclerosis	7.29e-06	5.5e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	7.28e-06	5.5e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—atherosclerosis	7.27e-06	5.49e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—atherosclerosis	7.23e-06	5.46e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	7.17e-06	5.42e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—atherosclerosis	7.17e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	7.16e-06	5.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—atherosclerosis	7.15e-06	5.4e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	7.14e-06	5.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	7.14e-06	5.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	7.11e-06	5.37e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAV1—atherosclerosis	7.1e-06	5.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—atherosclerosis	7.09e-06	5.35e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—atherosclerosis	7.09e-06	5.35e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOA1—atherosclerosis	7.09e-06	5.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CD36—atherosclerosis	7.08e-06	5.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—atherosclerosis	7.05e-06	5.33e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—atherosclerosis	7.05e-06	5.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	7.04e-06	5.32e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—atherosclerosis	7.03e-06	5.31e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LPL—atherosclerosis	7.02e-06	5.3e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	6.98e-06	5.27e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	6.97e-06	5.27e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—atherosclerosis	6.96e-06	5.26e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LPL—atherosclerosis	6.96e-06	5.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—atherosclerosis	6.94e-06	5.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—atherosclerosis	6.92e-06	5.22e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	6.86e-06	5.18e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	6.85e-06	5.18e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—atherosclerosis	6.85e-06	5.17e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—atherosclerosis	6.85e-06	5.17e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	6.84e-06	5.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—atherosclerosis	6.82e-06	5.15e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—atherosclerosis	6.8e-06	5.13e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—atherosclerosis	6.79e-06	5.13e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—atherosclerosis	6.74e-06	5.09e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—atherosclerosis	6.73e-06	5.09e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—atherosclerosis	6.71e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CD36—atherosclerosis	6.67e-06	5.04e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—atherosclerosis	6.63e-06	5.01e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CD36—atherosclerosis	6.61e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	6.61e-06	4.99e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARA—atherosclerosis	6.58e-06	4.97e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—atherosclerosis	6.54e-06	4.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	6.51e-06	4.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	6.48e-06	4.89e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—atherosclerosis	6.47e-06	4.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	6.46e-06	4.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	6.39e-06	4.83e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—atherosclerosis	6.37e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NOS3—atherosclerosis	6.34e-06	4.79e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	6.33e-06	4.78e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—atherosclerosis	6.32e-06	4.77e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—atherosclerosis	6.27e-06	4.73e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	6.27e-06	4.73e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	6.25e-06	4.72e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—atherosclerosis	6.24e-06	4.72e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—atherosclerosis	6.24e-06	4.71e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	6.22e-06	4.7e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARA—atherosclerosis	6.2e-06	4.68e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAV1—atherosclerosis	6.19e-06	4.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	6.18e-06	4.67e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOA1—atherosclerosis	6.17e-06	4.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	6.17e-06	4.66e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARA—atherosclerosis	6.15e-06	4.64e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—atherosclerosis	6.12e-06	4.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	6.11e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	6.07e-06	4.58e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—atherosclerosis	6.01e-06	4.54e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	5.99e-06	4.52e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—atherosclerosis	5.95e-06	4.5e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—atherosclerosis	5.88e-06	4.44e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—atherosclerosis	5.83e-06	4.41e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAV1—atherosclerosis	5.83e-06	4.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOA1—atherosclerosis	5.82e-06	4.39e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	5.81e-06	4.39e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—atherosclerosis	5.8e-06	4.38e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAV1—atherosclerosis	5.78e-06	4.36e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOA1—atherosclerosis	5.77e-06	4.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.64e-06	4.26e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—atherosclerosis	5.61e-06	4.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	5.52e-06	4.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	5.49e-06	4.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	5.47e-06	4.13e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—atherosclerosis	5.44e-06	4.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	5.42e-06	4.09e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NOS3—atherosclerosis	5.37e-06	4.05e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—atherosclerosis	5.33e-06	4.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	5.33e-06	4.02e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5.31e-06	4.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	5.3e-06	4e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	5.28e-06	3.99e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	5.26e-06	3.98e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	5.24e-06	3.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	5.23e-06	3.95e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	5.22e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	5.2e-06	3.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	5.15e-06	3.89e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—atherosclerosis	5.13e-06	3.87e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—atherosclerosis	5.08e-06	3.84e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—atherosclerosis	5.03e-06	3.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	4.99e-06	3.77e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—atherosclerosis	4.98e-06	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	4.96e-06	3.75e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	4.95e-06	3.74e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	4.94e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—atherosclerosis	4.91e-06	3.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	4.91e-06	3.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	4.9e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	4.89e-06	3.7e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—atherosclerosis	4.89e-06	3.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	4.85e-06	3.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	4.85e-06	3.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	4.84e-06	3.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	4.83e-06	3.64e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	4.81e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	4.81e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	4.8e-06	3.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	4.76e-06	3.6e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	4.75e-06	3.59e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NOS3—atherosclerosis	4.68e-06	3.53e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—atherosclerosis	4.61e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—atherosclerosis	4.57e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—atherosclerosis	4.57e-06	3.45e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	4.48e-06	3.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	4.46e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	4.44e-06	3.35e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	4.44e-06	3.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	4.41e-06	3.33e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NOS3—atherosclerosis	4.41e-06	3.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	4.4e-06	3.32e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	4.4e-06	3.32e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—atherosclerosis	4.38e-06	3.31e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NOS3—atherosclerosis	4.37e-06	3.3e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	4.36e-06	3.29e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—atherosclerosis	4.28e-06	3.23e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	4.24e-06	3.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	4.22e-06	3.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	4.22e-06	3.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	4.2e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	4.16e-06	3.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	4.11e-06	3.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	4.09e-06	3.09e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	4.08e-06	3.08e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	4.04e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	4.04e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—atherosclerosis	4.03e-06	3.04e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—atherosclerosis	4e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—atherosclerosis	3.39e-06	2.56e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—atherosclerosis	3.1e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—atherosclerosis	3.08e-06	2.33e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—atherosclerosis	3.07e-06	2.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—atherosclerosis	3.04e-06	2.3e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—atherosclerosis	2.92e-06	2.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.86e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	2.84e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	2.83e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	2.81e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—atherosclerosis	2.47e-06	1.86e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—atherosclerosis	2.15e-06	1.62e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—atherosclerosis	2.03e-06	1.53e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—atherosclerosis	2.01e-06	1.52e-05	CbGpPWpGaD
